Brilliant Violet 605™ anti-mouse CD19 Antibody

Product Details

Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Mouse CD19-expressing K562 human erythroleukemia cells

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence⁷.

Application References

(PubMed link indicates BioLegend citation)

1. Shoham T, et al. 2003. J. Immunol. 171:4062. (FC)
2. Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC)
3. Kamimura D, et al. 2006. J. Immunol. 177:306. (FC)
4. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC)
5. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
6. Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC)
7. Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed
8. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
9. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
10. Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed
11. Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed
12. Olive V, et al. 2013. Elife. 2:822. PubMed
13. Miyai T, et al. 2014. PNAS. 111:11780. PubMed

Product Citations

1. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
2. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
3. Van Winkle JA et al. 2018. Cell host & microbe. 24(5):665-676 . PubMed
4. Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed
5. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
6. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
7. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
8. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
9. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
10. John S, et al. 2020. Sci Rep. 10:11377. PubMed
11. Pokrovskii M, et al. 2019. Immunity. 51:185. PubMed
12. Li J, et al. 2018. Immunity. 49:178. PubMed
13. Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed
14. Benhamou D, et al. 2018. Front Immunol. 2.260416667. PubMed
15. Colliou N, et al. 2015. Toxins. 7: 3805 - 3817. PubMed
16. Bramwell K, et al. 2015. J Immunol. 195: 1647 - 1656. PubMed
17. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
18. Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
19. Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
20. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
21. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
22. White JM, et al. 2020. Mol Pharm. 2.165972222. PubMed
23. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
24. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
25. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
26. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
27. Maisonneuve C, et al. 2021. Cell Reports. 34(4):108677. PubMed
28. Earnest JT, et al. 2021. Cell Reports. 35(1):108962. PubMed
29. Nascimento DC, et al. 2021. Immunity. :. PubMed
30. Hutter K, et al. 2020. FEBS J. . PubMed
31. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
32. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
33. Subramaniam N, et al. 2021. Blood Adv. 5:1259. PubMed
34. Zhang R, et al. 2021. MAbs. 13:1904546. PubMed
35. van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed
36. Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
37. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
38. Tummala G, et al. 2021. Invest Ophthalmol Vis Sci. 62:41. PubMed
39. Parigger T, et al. 2021. Int J Mol Sci. 22:. PubMed
40. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
41. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
42. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
43. Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed
44. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
45. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
46. Kitajima Y, et al. 2022. Cells. 11:. PubMed
47. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
48. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
49. Gawish R, et al. 2022. Elife. 11:. PubMed
50. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
51. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
52. Collin R, et al. 2020. J Immunol. 205:133. PubMed
53. Shenoy AT, et al. 2022. Cytometry A. 101:892. PubMed
54. Kim E, et al. 2022. Immunity. 55:145. PubMed
55. Paik D, et al. 2022. Nature. 603:907. PubMed
56. Xiong E, et al. 2023. Front Immunol. 13:1083119. PubMed
57. Stravokefalou V, et al. 2023. Front Immunol. 13:1014802. PubMed
58. Arruda DC, et al. 2022. J Control Release. 350:228. PubMed
59. Christian DA, et al. 2022. Sci Immunol. 7:eabq7432. PubMed
60. Rege SV, et al. 2023. Commun Biol. 6:292. PubMed

RRID

AB_11203538 (BioLegend Cat. No. 115539)
AB_2563067 (BioLegend Cat. No. 115540)

Antigen Details

Structure

Ig superfamily, associates with CD21 and CD81, 95 kD

Distribution

Pro-B cells to mature B cells (during development), follicular dendritic cells

Function

Modulates B cell activation and differentiation

Ligand/Receptor

CD21, CD81, Leu-13

Cell Type

B cells, Dendritic cells

Biology Area

Costimulatory Molecules, Immunology

Molecular Family

CD Molecules

Antigen References

1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341.
2. Krop I, et al. 1996. Eur. J. Immunol. 26:238.
3. Krop I, et al. 1996. J. Immunol. 157:48.
4. Tedder TF, et al. 1994. Immunol. Today 15:437.

Gene ID

12478 View all products for this Gene ID

UniProt

View information about CD19 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis